UPPSALA,
Starting 2024 with a positive EBITDA
Q1 2024 highlights
- Total net revenues of
SEK 139.3 m (158.8) - EBITDA of
SEK 15.9 m (-41.1) - Net earnings of
SEK -8.9 m (-63.9) - US Commercial segment net revenues of
SEK 129.3 m (140.3), in local currencyUSD 12.4 m (13.5) - Cash flow from operating activities of
SEK -18.9 m (-61.6), cash and invested funds ofSEK 198.0 m (278.9) - Earnings per share before and after dilution amounted to
SEK -0.26 (-1.86) - MODIA® and Vorvida® were reimbursed within the US Veterans Affairs Federal Supply Schedule as of
January 1, 2024 - Data from the clinical phase 1 study and stability data for OX640, a nasal epinephrine powder product, were presented at the
American Academy of Allergy , Asthma & Immuniology Annual Meeting inWashington DC -
Orexo and Sobi agreed to advance feasibility study where AmorphOX® is tested with one of their biomolecules - To refinance the existing bond a four year senior secured social bond of
SEK 500 million was issued - The new bond was classified as a social bond after a social financing framework was established, which underwent an independent review by Morningstar Sustainalytics.
Important events after the end of the period
- Second patent in the US granted for OX640.
SEK m unless otherwise stated |
2024 |
2023 |
2023 |
Net revenues |
139.3 |
158.8 |
638.8 |
Cost of goods sold |
-13.3 |
-28.7 |
-88.9 |
Operating expenses |
-130.7 |
-189.4 |
-659.5 |
EBIT |
-4.7 |
-59.3 |
-109.5 |
EBIT margin |
-3.4 % |
-37.4 % |
-17.1 % |
EBITDA |
15.9 |
-41.1 |
-32.5 |
Earnings per share. before dilution. SEK |
-0.26 |
-1.86 |
-3.73 |
Earnings per share. after dilution. SEK |
-0.26 |
-1.86 |
-3.73 |
Cash flow from operating activities |
-18.9 |
-61.6 |
-95.0 |
Cash and invested funds |
198.0 |
278.9 |
171.0 |
CEO Comments in brief: Creating a stable financial platform
I am pleased to report a significant improvement in our financial results with an EBITDA increasing
For the full CEO Comments read the PDF
Contact persons quarterly report
Presentation
On
To attend via teleconference where you can ask questions verbally:
https://conference.financialhearings.com/teleconference/?id=50048736
When registered you will be provided phone numbers and a conference ID to access the conference.
To attend via webcast:
https://ir.financialhearings.com/orexo-q1-report-2024
Prior to the call, presentation material will be available on the website under Investors/ Reports/Audiocasts.
This information is information that
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/orexo/r/orexo-q1-2024-interim-report,c3975281
The following files are available for download:
|
View original content:https://www.prnewswire.co.uk/news-releases/orexo-q1-2024-interim-report-302139334.html